Semaglutide for Type 2 Diabetes
Verdict: Published
Across 6 PubMed studies, the evidence for Semaglutide in Type 2 Diabetes grades Tier A — moderate evidence.
A 🔵 A Moderate Evidence Published
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.76
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published
Confidence
92%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.76
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Finding: Pooling 4 RCTs (SUSTAIN 6, PIONEER 6, FLOW, SOUL; 9,831 semaglutide vs 9,832 control), semaglutide reduced 3-point MACE with HR 0.83 (95% CI 0.76-0.91), a 17% relative risk reduction, plus reductions in nonfatal MI (HR 0.79, 95% CI 0.67-0.92) and revascularization (HR 0.71, 95% CI 0.61-0.83), while cardiovascular death, all-cause death and nonfatal stroke were not significantly reduced.
View on PubMed Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Finding: In type 2 diabetes patients at high cardiovascular risk, once-weekly subcutaneous semaglutide reduced the primary MACE composite to 6.6% vs 8.9% with placebo (HR 0.74, 95% CI 0.58-0.95; P<0.001 for noninferiority and P=0.02 for superiority), driven mainly by fewer nonfatal strokes and MIs.
View on PubMed Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER-6)
Finding: Oral semaglutide was noninferior but NOT superior to placebo for MACE (3.8% vs 4.8%; HR 0.79, 95% CI 0.57-1.11; P<0.001 for noninferiority, P=0.17 for superiority); cardiovascular death (HR 0.49) and all-cause death (HR 0.51) were nominally lower but the trial was not powered for superiority.
View on PubMed Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
Finding: Across 11 RCTs (9,821 patients), oral semaglutide lowered HbA1c vs placebo by 1.06% (7 mg; 95% CI 0.81-1.30) and 1.10% (14 mg; 95% CI 0.88-1.31), and modestly more than active comparators (14 mg: 0.38%, 95% CI 0.31-0.45), with significant weight loss but dose-dependent gastrointestinal adverse events and more discontinuation at 14 mg.
View on PubMed Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis
Finding: Across 10 RCTs (9,541 patients), oral semaglutide reduced HbA1c vs placebo in a dose-dependent manner (3 mg: -0.61%, 95% CI -0.89 to -0.34; 7 mg: -1.12%, 95% CI -1.45 to -0.79; 14 mg: -1.08%, 95% CI -1.32 to -0.85) and modestly more than active comparators, with additional weight, fasting glucose and BMI benefits.
View on PubMed Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis
Finding: Across 13 trials (6 placebo- and 7 active-controlled, predominantly subcutaneous), semaglutide reduced HbA1c vs placebo by 1.01% (0.5 mg; 95% CI 0.56-1.47) and 1.38% (1 mg; 95% CI 1.05-1.70) and body weight by 4.11 kg (1 mg; 95% CI -4.85 to -3.37), confirming robust dose-dependent glycaemic and weight efficacy.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app… source↗
L4b EU EFSA
Supportive
Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a… source↗
L4c UK NHS
Supportive
Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th… source↗
L4d TW TFDA / 衛福部
Supportive
胰妥讚 注射劑 Ozempic solution for injection 衛部菌疫輸字第001107 號；主成分 Semaglutide 1.34mg/mL,3mL；適應症：用於第二型糖尿病成人病人作為飲食和運動之輔助療法，以單一療法或與其他糖尿病治療藥品併用方式，治療控制不佳之第二型糖尿病；對於第二型糖尿病合併已確診心血管疾病之病人，可降低主要不良心血管事件之風險。健保給付規定：限第二型糖尿病病人經 metformin 及/或 sulfonylurea 兩類藥品最大耐受劑量，及繼續使用下列藥品其中之一達 6 個月後 HbA1c 仍 ≥8.5% 者使用。 source↗
L4e WHO
Supportive
GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity. [...] GLP-1 receptor agonists – semaglutide, dulaglutide and liraglutide [added to EML] for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity (defined as body mass index (BMI) ≥ 30kg/m2). [...] High prices of medicines like… source↗
L5a NIH Office of Dietary Supplements
Supportive
Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription GLP-1 medication used for weight loss and weight management, type 2 diabetes treatment, or to reduce the risk of chronic kidney disease and major cardiovascular events in certain patients with type 2 diabetes. Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated steatohepatitis (MASH), without cirrhosis of the live… source↗
L5b Mayo Clinic
Supportive
Semaglutide injection is used to treat type 2 diabetes, and it is used together with diet and exercise to help control your blood sugar. This medicine is also used to lower the risk of heart attack, stroke, or death in patients with type 2 diabetes, obesity, and heart or blood vessel disease. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Ozempic is approved to lower blood s… source↗
L5c Cleveland Clinic
Supportive
SEMAGLUTIDE (SEM a GLOO tide) treats type 2 diabetes. It works by increasing insulin levels in your body, which decreases your blood sugar (glucose). It may also be used to lower the risk of heart attack and stroke in people with type 2 diabetes. source↗
L5d Harvard Health
Supportive
GLP-1 receptor agonists like semaglutide (Ozempic), liraglutide (Victoza), and tirzepatide (Mounjaro) help by increasing insulin secretion in response to meals, thereby lowering blood sugar levels. GLP-1 drugs lower blood sugar only when it's high, unlike insulin, which works regardless of glucose levels. GLP-1 receptor agonists also reduce the likelihood of developing heart-related problems su… source↗
L5e Specialty Society (condition-mapped)
Supportive
Agents with very high efficacy for glucose lowering include dulaglutide (high dose), semaglutide, tirzepatide, insulin, combination oral regimens, or combination injectable regimens. For individuals with diabetes who are overweight or obese, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist (GLP-1 RA) such as semaglutide, or dual glucose-dependent insulinotropic… source↗